Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Medicare issued a favorable local coverage determination (LCD) for donor-derived cell-free DNA (dd-cfDNA) testing, expanding reimbursement for transplant organ monitoring. The policy increases surveillance testing frequencies across kidney and heart transplants compared to previous guidelines, supporting iMDx's commercial strategy for in-house testing kits. The company's flagship GraftAssureCore test is reimbursed at $2,753 per result, while GraftAssureDx awaits FDA marketing authorization.